Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 11, 2013 - Issue 9
Submit an article Journal homepage
1,221
Views
63
CrossRef citations to date
0
Altmetric
Reviews

Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis

Seyedmojtaba SeyedmousaviDepartment of Medical Microbiology, Radboud University Nijmegen Medical centre, Nijmegen, The Netherlands;Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, The Netherlands
,
Johan W MoutonDepartment of Medical Microbiology, Radboud University Nijmegen Medical centre, Nijmegen, The Netherlands;Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, The Netherlands
,
Paul E VerweijDepartment of Medical Microbiology, Radboud University Nijmegen Medical centre, Nijmegen, The Netherlands;Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, The Netherlands
&
Roger JM BrüggemannNijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, The Netherlands;Department of Pharmacy, Radboud University Nijmegen Medical centre, Nijmegen, The NetherlandsCorrespondence[email protected]
Pages 931-941 | Published online: 10 Jan 2014

References

  • van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther. Drug Monit. 21(1), 63–73 (1999).
  • Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408–415 (2002).
  • Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3), 327–360 (2008).
  • Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am. J. Respir. Crit. Care Med. 170(6), 621–625 (2004).
  • Denning DW. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23(3), 608–615 (1996).
  • Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am. 16(4), 875–894, vi (2002).
  • van der Linden JW, Snelders E, Kampinga GA et al. Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009. Emerg. Infect. Dis. 17(10), 1846–1854 (2011).
  • Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348–359 (2007).
  • Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335–347 (2007).
  • Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. North Am. 17(1), 159–191, ix (2003).
  • Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy 28(5), 614–645 (2008).
  • Warrilow AG, Martel CM, Parker JE et al. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob. Agents Chemother. 54(10), 4235–4245 (2010).
  • Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34(5), 563–571 (2002).
  • Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36(9), 1122–1131 (2003).
  • Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366(9495), 1435–1442 (2005).
  • Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46(8), 2546–2553 (2002).
  • Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1), 17–23 (2003).
  • Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1), 10–16 (2003).
  • Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75(6), 587–588 (2004).
  • Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob. Agents Chemother. 56(6), 3032–3042 (2012).
  • Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53(3), 935–944 (2009).
  • Barchiesi F, Arzeni D, Fothergill AW et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob. Agents Chemother. 44(1), 226–229 (2000).
  • Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36(10), 2950–2956 (1998).
  • Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. 41(5), 1124–1126 (1997).
  • Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 48(10), 4063–4066 (2004).
  • Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. 45(3), 857–869 (2001).
  • Najvar LK, Cacciapuoti A, Hernandez S et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob. Agents Chemother. 48(3), 758–764 (2004).
  • Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. 44(3), 780–782 (2000).
  • Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41(7), 1504–1507 (1997).
  • Krishna G, Ma L, Martinho M, Preston RA, O’Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67(11), 2725–2730 (2012).
  • Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47(9), 2788–2795 (2003).
  • Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 48(9), 3543–3551 (2004).
  • Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57(2), 218–222 (2004).
  • Ruping MJ, Albermann N, Ebinger F et al. Posaconazole concentrations in the central nervous system. J. Antimicrob. Chemother. 62(6), 1468–1470 (2008).
  • Ghosal A, Hapangama N, Yuan Y et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos. 32(2), 267–271 (2004).
  • Welzen ME, Brüggemann RJ, Van Den Berg JM et al. A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease. Pediatr. Infect. Dis. J. 30(9), 794–797 (2011).
  • Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46(2), 201–211 (2008).
  • Ueda K, Nannya Y, Kumano K et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int. J. Hematol. 89(5), 592–599 (2009).
  • Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16(7), 927–933 (2010).
  • Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50(1), 27–36 (2010).
  • Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55(10), 4782–4788 (2011).
  • Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob. Agents Chemother. 56(9), 4793–4799 (2012).
  • Park WB, Kim NH, Kim KH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin. Infect. Dis. 55(8), 1080–1087 (2012).
  • Mitsani D, Nguyen MH, Shields RK et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob. Agents Chemother. 56(5), 2371–2377 (2012).
  • Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis. 21(6), 580–586 (2008).
  • Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther. Drug Monit. 34(1), 72–76 (2012).
  • Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44(1), 2–12 (2007).
  • Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88(1), 115–119 (2010).
  • Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89(3), 351–352 (2011).
  • Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56(11), 5503–5510 (2012).
  • Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med. Mycol. 46(2), 97–112 (2008).
  • Brüggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48(10), 1441–1458 (2009).
  • Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46(2), 235–243 (2006).
  • Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35(5), 509–513 (2005).
  • Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin. Infect. Dis. 39(8), 1241–1244 (2004).
  • Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J. Clin. Pharm. Ther. 34(3), 301–311 (2009).
  • Seyedmousavi S, Brüggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J. Antimicrob. Chemother.68(2), 385–393 (2013).
  • Mavridou E, Brüggemann RJ, Melchers WJ, Verweij PE, Mouton JW. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54(11), 4758–4764 (2010).
  • Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54(2), 860–865 (2010).
  • Lewis RE. Current concepts in antifungal pharmacology. Mayo. Clin. Proc. 86(8), 805–817 (2011).
  • Storzinger D, Borghorst S, Hofer S et al. Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit. Antimicrob. Agents Chemother. 56(8), 4468–4470 (2012).
  • Vehreschild JJ, Muller C, Farowski F et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur. J. Clin. Pharmacol. 68(6), 987–995 (2012).
  • Spriet I, Brüggemann RJ, Annaert P et al. Pharmacokinetic profile of voriconazole in a critically Ill patient on therapeutic plasma exchange. Ther. Drug Monit. 35(1), 141–143 (2013).
  • Fuhrmann V, Schenk P, Jaeger W et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J. Antimicrob. Chemother. 60(5), 1085–1090 (2007).
  • Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit. Care Clin. 22(2), 255–271 (2006).
  • Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin. Infect. Dis. 45(2), 205–216 (2007).
  • Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(1), 39–44 (2010).
  • Decosterd LA, Rochat B, Pesse B et al. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob. Agents Chemother. 54(12), 5303–5315 (2010).
  • Wissen CP, Burger DM, Verweij PE et al. Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 887–888, 79–84 (2012).
  • Brüggemann RJ, Touw DJ, Aarnoutse RE, Verweij PE, Burger DM. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob. Agents Chemother. 53(1), 303–305 (2009).
  • Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50(4), 1570–1572 (2006).
  • Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 56(3), 304–310 (2013).
  • Brüggemann RJ, Blijlevens NM, Burger DM, Franke B, Troke PF, Donnelly JP. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 65(1), 107–113 (2010).

Websites

  • EMA. European public assessment report (EPAR) for Noxafil. European Medicines Agency (2012). www.ema.europa.eu/ema/( Accessed 1 April 2013)
  • EMA. European public assessment report (EPAR) for Vfend. (European Medicines Agency (2012). www.ema.europa.eu/ema/ ( Accessed 1 April 2013)
  • Guidance for Industry. Bioanalytical Method Validation In: US Department of Health and Human Services, Center for Drug Evaluation and Research, Food and Drug Administration (2001). www.fda.gov/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.